2008
DOI: 10.1152/ajplung.00428.2007
|View full text |Cite
|
Sign up to set email alerts
|

Endothelial cell barrier protection by simvastatin: GTPase regulation and NADPH oxidase inhibition

Abstract: The statins, hydroxy-3-methylglutaryl-CoA reductase inhibitors that lower serum cholesterol, exhibit myriad clinical benefits, including enhanced vascular integrity. One potential mechanism underlying increased endothelial cell (EC) barrier function is inhibition of geranylgeranylation, a covalent modification enabling translocation of the small GTPases Rho and Rac to the cell membrane. While RhoA inhibition attenuates actin stress fiber formation and promotes EC barrier function, Rac1 inhibition at the cell m… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

8
90
1

Year Published

2009
2009
2014
2014

Publication Types

Select...
6
3
1

Relationship

3
7

Authors

Journals

citations
Cited by 89 publications
(99 citation statements)
references
References 45 publications
8
90
1
Order By: Relevance
“…Circulating blood cells from septic patients generate higher levels of phorbol ester-stimulated O 2 À production compared with those in control subjects, and this activation is inhibited by simvastatin, a widely used cholesterolreducing drug (28). Further, recent data indicate that simvastatin markedly decreases LPS-induced O 2 À production in human pulmonary artery ECs via dual inhibitory effects on RhoA and Rac1 (17). Together, these studies suggest that excessive generation of ROS by activation of phagocytic and nonphagocytic NOX enzymes may induce endothelial damage or activation with the subsequent loss of barrier function and pulmonary edema or both, key features of ALI=ARDS.…”
Section: Nox Enzymes In Acute Lung Injurymentioning
confidence: 79%
“…Circulating blood cells from septic patients generate higher levels of phorbol ester-stimulated O 2 À production compared with those in control subjects, and this activation is inhibited by simvastatin, a widely used cholesterolreducing drug (28). Further, recent data indicate that simvastatin markedly decreases LPS-induced O 2 À production in human pulmonary artery ECs via dual inhibitory effects on RhoA and Rac1 (17). Together, these studies suggest that excessive generation of ROS by activation of phagocytic and nonphagocytic NOX enzymes may induce endothelial damage or activation with the subsequent loss of barrier function and pulmonary edema or both, key features of ALI=ARDS.…”
Section: Nox Enzymes In Acute Lung Injurymentioning
confidence: 79%
“…These activities of statins may be associated with Rho/Rho kinase signaling Statins can inhibit the prenylation of Ras and Rho leading to inactivation of Rhp/Rho kinase which then delays the development of atherosclerosis (Chiba et al, 2008;Chen et al, 2008 Abbreviations: Flu, Fluvastatin; TNF-, tumor necrosis factor-; TF, tissue factor; HUVECs, human umbilical vein endothelial cells; ELISA, enzyme-linked immunosorbent assay; RT-PCR, real time polymerase chain reaction; mRNA, messenger ribonucleic acid; MVA, mevalonic acid; cDNA, complementary deoxyribonucleic acid; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; PVDF, polyvinylidene fluoride; TBST, TRIS-Buffered Saline Tween-20; DMEM, Dulbecco's modified eagle's medium.…”
Section: Discussionmentioning
confidence: 99%
“…Using pharmacologic inhibitors that target ROCK, previous studies have demonstrated an important role for ROCK in regulating endothelial cell (EC) actin cytoskeleton organization and permeability increases during an inflammatory response in vivo and in vitro, especially during the early and acute phase of the inflammatory responses (13,14). All these inhibitors similarly inhibit ROCK1 and ROCK2.…”
Section: R Ho Kinase (Rock)mentioning
confidence: 99%